• J3/31 A-3 Khiri Extention Malviya Nagar, New Delhi-17
  • macnispharma@gmail.com
  • Working Hours - Mon - Fri: 9:30 - 18:30

RABENIS DSR

RABENIS DSR

RABENIS DSR

For the use only of a Registered Medical Practitioner or Hospital or a Laboratory

Abbreviated Prescribing information for RABENIS DSR (Rabeprazole sodium 20 mg and Domperidone 30 mg sustained release capsules)

[Please refer the complete prescribing information available at www.macnispharma.com ]

PHARMACOLOGICAL PROPERTIES: Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) which suppress gastric acid secretion. Domperidone is a unique gastrokinetic and antiemetic drug. 

INDICATION: For the treatment of Gastroesophageal reflux disease (GERD) that is not treated adequately with PPIs or H2 Receptor Antagonist (H2RA) alone.   

DOSAGE AND ADMINISTRATION: One capsule once daily preferably before meal. 

CONTRAINDICATION: Patients with known hypersensitivity to rabeprazole sodium, substituted benzimidazoles, domperidone or to any excipient used in the formulation. In patients with prolactinoma, gastro-intestinal haemorrhage, mechanical obstruction or perforation, severe hepatic impairment, prolonged cardiac conduction intervals (particularly QTc), significant electrolyte disturbances or underlying cardiac diseases and in patients receiving potent CYP3A4 inhibitors and QT-prolonging drugs. 

WARNINGS & PRECAUTIONS: Symptomatic response to therapy with rabeprazole does not preclude the presence of gastric malignancy. Monitor for increases in INR and prothrombin time when used with warfarin. Risk of acute interstitial nephritis, Clostridium difficile associated diarrhoea, prolongation of QT interval and neurological side effects in young children. On prolonged therapy risk of cyanocobalamin (vitamin B-12) Deficiency, bone fracture and hypomagnesemia. Dose reduction required in patients with renal impairment. 

DRUG INTERACTIONS: Interact with QT-prolonging drugs (for ex. erythromycin, levofloxacin, cisapride etc.), CYP3A4 inhibitors (for ex. systemic azole antifungals, diltiazem etc), bradycardia and hypokalaemia-inducing drugs (for ex. azithromycin and roxithromycin) warfarin, cyclosporine, ketoconazole, iron salts, digoxin, mycophenolate mofetil, atazanavir and methotrexate when used concomitantly. 

ADVERSE REACTIONS: Pain, pharyngitis, flatulence, infection, constipation, abdominal pain, diarrhoea, headache, sudden cardiac death, coma, jaundice, rhabdomyolysis, anaphylaxis, severe dermatologic reactions, including toxic epidermal necrolysis (some fatal), Stevens-Johnson syndrome, interstitial pneumonia, convulsion, extrapyramidal disorder, ventricular arrhythmias, Torsade de Pointes, urinary retention, gynaecomastia and amenorrhoea. 

MARKETED BY:

MACNIS PHARMACEUTICALS

J3/31 A-3,3rd Floor,Khiri Extension.

Malviya Nagar,New Delhi-17


Visit us at: www.macnispharma.com

Reach us at: info@macnispharma.com